ArticleBMC musculoskeletal disorders2025
Soft tissue reconstruction using Trevira tube following proximal femur resection and tumorous endoprosthetic replacement.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of Trevira tubes is beneficial for soft tissue reconstruction following proximal femur resection and endoprosthetic replacement, enhancing joint stability, mobility, and reducing abductor insufficiency. The purpose of the study is to describe the surgical technique and outcomes of soft tissue reconstruction using a Trevira tube following proximal femur resection for malignant bone tumors.
methodsThis study evaluates the outcomes of 80 patients who underwent proximal femur tumor replacement using dual-mobility hip systems with Trevira tubes in a sarcoma center. Reconstruction revision-free survival rate and failure modes were assessed using the Henderson classification, while functional outcomes were evaluated in 51 patients with a minimum six-month follow-up, assessed using the Harris Hip Score(HHS), Mayo Hip Score(MHS), Musculoskeletal Tumor Society Score(MSTS), Trendelenburg sign, and range of motion.
resultsThe five-year revision-free survival rate was 85.3%. The cumulative incidences at the five-year mark were 6.5% for dislocation and 8.1% for deep infection. Failures occurred predominantly in the early postoperative period (3 ± 2.4 months). Functional outcomes (HHS: 78.71 ± 12.55, MHS: 75.68 ± 13.37 and MSTS: 24.11 ± 3.22) were generally satisfactory, despite the frequent occurrence of abductor muscle insufficiency (37.3%). Statistically significant predictors of survival or functional outcomes were not identified. Nevertheless, trends indicate that patients with pathological fractures and metastases tend to have less favorable outcomes.
conclusionTrevira tube for soft tissue reconstruction following proximal femur resection and endoprosthetic replacement demonstrated promising results, with low failure rates and favorable functional outcomes. While no statistically significant predictors of survival or functional outcomes were identified, trends suggested poorer outcomes in patients with pathological fractures or metastatic bone disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.